Transdermal Specialties Global, Inc.

Cover Block

PUBLIC

Attribute	Value
Name	Transdermal Specialties Global, Inc.
Tagline	Needle-free transdermal insulin patch using ultrasound.
Headquarters	Frederick, MD, United States
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Founding Team	Solo Founder (Bruce K. Redding Jr.)

Links

PUBLIC

• Website: https://u-strip.com/
• LinkedIn: https://www.linkedin.com/company/transdermal-specialties-global-inc/

Data Accuracy: GREEN -- Website URL confirmed by company sources; LinkedIn page is a standard corporate profile.

Executive Summary

PUBLIC Transdermal Specialties Global is a pre-revenue biotech venture developing a needle-free insulin patch, a proposition that remains compelling for its potential to address patient non-compliance and discomfort in a massive chronic disease market, but its current viability is clouded by a 2021 bankruptcy filing and a lack of recent operational momentum. The company was founded by Bruce K. Redding Jr., a former NASA mission specialist who holds over 60 patents, and its core technology, the U-Strip™, uses ultrasound to temporarily expand skin pores for transdermal delivery of large-molecule drugs like insulin [Drug Development & Delivery, 2016] [BioBuzz]. The company's historical claims include a production capacity exceeding one million patches per week at a facility in Charlotte, North Carolina, and a pipeline of over 175 compounds [Drug Development & Delivery, 2016]. No funding rounds, customers, or strategic partnerships have been publicly disclosed, and the business model appears oriented toward eventual B2B licensing or partnership with larger pharmaceutical entities. The key near-term milestone, according to the company's website, is the readiness of a closed-loop system for clinical trials in 2026, though this timeline is unverified by independent sources [company website]. Investors should watch for any evidence of post-bankruptcy restructuring, new capital infusion, or validated progress toward clinical trials as the primary signals for a potential revival of the venture.

Data Accuracy: YELLOW -- Key historical claims are sourced from a single 2016 trade publication interview; bankruptcy and relocation are confirmed.

Taxonomy Snapshot

Axis	Value
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Founding Team	Solo Founder

Company Overview

PUBLIC

Transdermal Specialties Global, Inc. (TSG) is a biotechnology company incorporated in Maryland, focused on developing needle-free transdermal drug delivery systems. The company's public narrative centers on its patented U-Strip™ technology, which uses ultrasound to facilitate the delivery of large-molecule drugs like insulin through the skin. Its headquarters are listed in Frederick, Maryland, following a relocation from Charlotte, North Carolina, announced in October 2020 [PRWeb, October 2020].

The company was founded by Bruce K. Redding Jr., a former NASA mission specialist who is listed as the inventor on numerous patents related to transdermal delivery [Justia Patents Search]. Public milestones are sparse and dated. A 2016 executive interview outlined plans for Phase III clinical trials for an insulin patch and claimed a production capacity exceeding one million patches per week at a Charlotte plant [Drug Development & Delivery, 2016]. The most recent public corporate action was a voluntary Chapter 11 bankruptcy filing on May 19, 2021 [PacerMonitor, 2021].

No subsequent funding rounds, customer announcements, or trial result publications from major medical or business outlets have been identified post-2021. The company's website remains active, with a blog post from February 2024 discussing a "new five-day transdermal insulin patch" and referencing a closed-loop system targeted for clinical trials in 2026 [company website, 2024]. However, the lack of independent verification for these claims and the 2021 bankruptcy filing create a significant gap in the operational timeline.

Data Accuracy: YELLOW -- Key entity facts (HQ, bankruptcy) are confirmed by public records; founder patent background is corroborated. Operational claims (capacity, trials) are from a single 2016 trade interview and unverified company statements.

Product and Technology

MIXED

The company's core innovation is the U-Strip™, a needle-free transdermal patch designed to deliver insulin using low-frequency ultrasound. The system aims to create a non-invasive alternative to injections for managing type 1 and type 2 diabetes [Drug Development & Delivery, 2016]. The patented technology uses ultrasound to temporarily expand skin pores, allowing the transdermal delivery of large-molecule drugs like insulin, which has historically been a significant technical barrier [Drug Development & Delivery, 2016].

Publicly available details on the product's current state are limited. A 2016 interview cited a production capacity of over one million patches per week at a facility in Charlotte, North Carolina [Drug Development & Delivery, 2016]. The company's website states an ambition to have a closed-loop U-Strip™ system ready for clinical trials in 2026, though this is an unverified roadmap claim [company website, undated]. Beyond insulin, the company has claimed a pipeline of over 175 compounds for potential transdermal delivery, including applications for central nervous system disorders [Drug Development & Delivery, 2016].

Data Accuracy: YELLOW -- Product claims are sourced from a 2016 trade interview and an undated company website, with no recent independent verification. The founder's patent portfolio is confirmed [Justia Patents Search].

Market Research and Opportunity

PUBLIC The addressable market for non-invasive drug delivery, particularly for chronic conditions like diabetes, is defined by a persistent patient demand for alternatives to daily injections and the high economic burden of disease management.

Third-party market sizing specific to needle-free insulin delivery is not available in the cited sources. For context, the global diabetes care devices market, which includes insulin pens, pumps, and syringes, was valued at approximately $30.7 billion in 2022 and is projected to grow to $45.2 billion by 2030, according to a Grand View Research report [Grand View Research, 2023]. The transdermal drug delivery systems segment within this broader market was valued at an estimated $6.5 billion in 2022 [Grand View Research, 2023]. These figures serve as an analogous market reference for the potential addressable space for a disruptive delivery technology.

Key demand drivers for a solution like the U-Strip™ are well-documented. The global prevalence of diabetes continues to rise, with the International Diabetes Federation reporting 537 million adults living with diabetes in 2021, a number projected to increase to 643 million by 2030 [IDF Diabetes Atlas, 2021]. Patient adherence remains a significant challenge; studies indicate needle phobia and the inconvenience of frequent injections contribute to non-compliance, which can lead to worse health outcomes and higher long-term costs [Journal of Diabetes Science and Technology, 2018]. A needle-free, long-wear patch could address these pain points directly.

Adjacent and substitute markets are substantial. Beyond insulin, the company's cited pipeline of 175+ compounds suggests a longer-term opportunity in central nervous system (CNS) disorders and other large-molecule therapeutics where traditional transdermal methods are ineffective [Drug Development & Delivery, 2016]. The primary competitive substitutes are not other patches but established injection methods and emerging technologies like smart insulin pens and implantable pumps. Regulatory pathways represent a significant macro force. Any new drug delivery system, especially one involving a new modality like ultrasound, must undergo rigorous FDA review for both device safety and drug efficacy, a process that is capital-intensive and time-consuming.

Global Diabetes Care Devices Market (2022) | 30.7 | $B
Projected Market (2030) | 45.2 | $B
Transdermal Delivery Systems Segment (2022) | 6.5 | $B

The analyst takeaway is that the underlying market need is large and growing, but the company's specific serviceable market remains unquantified and is contingent upon clinical and regulatory success. The technology's potential expansion into other therapeutic areas is a noted long-term lever, but it does not reduce the immediate market risk concentrated in diabetes.

Data Accuracy: YELLOW -- Market sizing is based on analogous, third-party industry reports. Company-specific SAM/SOM and pipeline validation are not publicly available.

Competitive Landscape

MIXED, Transdermal Specialties Global (TSG) operates in a high-stakes, capital-intensive segment where its needle-free insulin patch concept faces established incumbents and a new wave of non-invasive delivery challengers, though no direct named competitors are confirmed in public sources.

Without a named, funded, and publicly active competitor building an identical ultrasound-driven transdermal insulin patch, the competitive map must be drawn from broader market categories. The primary competitive set for TSG's U-Strip™ consists of three segments. First, the dominant incumbents are the large pharmaceutical and medical device companies that manufacture and distribute traditional insulin via syringes, pens, and pumps, such as Novo Nordisk, Eli Lilly, and Medtronic. Their advantage is an unassailable position in the standard of care, deep payer relationships, and massive commercial scale. Second, a growing cohort of challengers is developing alternative non-invasive insulin delivery methods, including inhaled insulin (like MannKind's Afrezza), oral insulin formulations in various clinical stages, and other transdermal approaches using microneedles or iontophoresis. Third, adjacent substitutes include emerging diabetes management technologies, such as continuous glucose monitors (CGMs) from Dexcom and Abbott, which, while not delivering insulin, are critical components of the automated insulin delivery (closed-loop) systems TSG aims to enter.

TSG's claimed defensible edge rests entirely on its proprietary U-Strip™ technology and the associated intellectual property. The company's patents around using ultrasound to expand skin pores for large-molecule delivery, including insulin, represent a technical barrier to entry [Justia Patents Search]. Founder Bruce Redding's background as a named inventor on numerous patents supports this claim [BioBuzz]. However, this edge is highly perishable. It is contingent on the company's ability to fund and complete late-stage clinical trials to demonstrate safety and efficacy, a process it has not publicly achieved. Without the capital to advance through regulatory milestones, the patent portfolio alone does not create a commercial moat. Furthermore, the edge in manufacturing scale, cited as a capacity of over one million patches per week at a Charlotte plant, dates from approximately 2016 and its current operational status is unverified [Drug Development & Delivery, 2016].

The company's most significant exposure is its lack of commercial infrastructure and recent financial distress. It filed for bankruptcy in May 2021 [PacerMonitor, 2021], which severely limits its ability to compete on capital, talent acquisition, or partnership development. This financial position leaves it vulnerable to well-funded competitors that can outpace its R&D. For instance, a large incumbent like Novo Nordisk, with its vast resources, could develop or acquire a competing transdermal technology and accelerate it through trials far more quickly than TSG. Similarly, TSG does not own any channel to patients or payers, a critical gap that established diabetes care companies have spent decades building.

The most plausible 18-month competitive scenario hinges on the company's ability to secure a lifeline. If TSG can attract a strategic partner or acquirer,perhaps a mid-sized pharmaceutical company seeking to bolster its diabetes pipeline,its technology and patents could find a path to validation and development. In this case, a "winner" could be a firm like MannKind, which has experience commercializing a novel, non-invasive insulin product and might integrate the transdermal patch into its portfolio. Conversely, if TSG remains dormant and undercapitalized, it is the clear "loser," and its technology risks being rendered obsolete by advances from other non-invasive delivery startups or incremental improvements from pump and CGM companies moving closer to a fully automated, needle-free system.

Data Accuracy: YELLOW, Competitive analysis is inferred from the broader diabetes care market due to a lack of named, direct competitors in sources. TSG's patent position is confirmed, but its operational and financial status post-2021 is based on a single public filing.

Opportunity

PUBLIC The core opportunity for Transdermal Specialties Global is to establish the first commercially viable, needle-free transdermal delivery system for large-molecule drugs, beginning with a multi-billion dollar addressable market in diabetes care.

The headline opportunity is the creation of a new drug delivery category standard. If the company's U-Strip™ technology can reliably deliver insulin and other biologics without needles, it would represent a fundamental shift in chronic disease management. The plausibility of this outcome rests on the technical claim, cited in a 2016 trade interview, that the platform can deliver molecules up to 125,000 Daltons transdermally, a significant leap over traditional passive patch limits [Drug Development & Delivery, 2016]. A successful insulin patch could serve as the beachhead, proving the system's safety and efficacy to regulators and pharmaceutical partners, and opening the door to a broader pipeline of 175+ compounds the company has cited [Drug Development & Delivery, 2016].

Growth from this initial foothold could follow several distinct paths, each with identifiable catalysts.

Scenario	What happens	Catalyst	Why it's plausible
Insulin Patch Commercialization	The company successfully brings its five-day insulin patch to market for type 1 and 2 diabetes patients.	FDA clearance following a completed Phase III clinical trial.	The company has stated its closed-loop system is targeted for clinical trials in 2026, indicating a defined development pathway [company website, undated]. A prior press release also claimed success for an insulin patch clinical trial, though without a date [Drug Development & Delivery, undated].
Pharmaceutical Partnership & Licensing	TSG transitions from a product company to a platform licensor, partnering with large pharma to deliver their proprietary biologics.	A strategic research arrangement or licensing deal with a named pharmaceutical company.	The company's 2016 interview mentioned "strategic research arrangements" and a drug screening program that had already yielded three non-insulin candidates for clinical study, suggesting a history of collaborative R&D [Drug Development & Delivery, 2016].

Compounding success would likely manifest as a technology and IP moat rather than a traditional network effect. Each new drug successfully formulated for the U-Strip™ platform would generate proprietary data on formulation and delivery kinetics for large molecules. This dataset would accelerate development for subsequent compounds, creating a learning curve advantage. Furthermore, securing regulatory approval for insulin,a high-risk, high-profile biologic,would de-risk the regulatory pathway for follow-on drugs in the company's pipeline, such as those for central nervous system (CNS) applications [Drug Development & Delivery, 2016]. Early manufacturing scale, with a claimed capacity of over one million patches per week at a Charlotte plant, was positioned to support this flywheel by enabling pilot production for partners [Drug Development & Delivery, 2016].

The size of the win, should the Insulin Patch Commercialization scenario succeed, can be framed by the diabetes care market. While a direct comparable is difficult given the novel nature of the technology, the global insulin delivery devices market was valued at over $30 billion in recent analyst reports. A needle-free transdermal patch capturing even a single-digit percentage of this established market would represent a multi-billion dollar revenue opportunity. This outcome is a scenario, not a forecast, and is entirely contingent on the technology achieving clinical and regulatory success where many previous transdermal attempts have failed.

Data Accuracy: ORANGE -- Key opportunity claims (pipeline, technical capabilities) are sourced from a single 2016 trade interview and un-dated website material. The 2026 trial target and bankruptcy filing are not reconciled in public information.

Sources

PUBLIC

1. [Drug Development & Delivery, 2016] Executive Interview: Transdermal Specialties - A New Dimension in Transdermal Drug Delivery | https://drug-dev.com/executive-interview-transdermal-specialties-a-new-dimension-in-transdermal-drug-delivery/

2. [BioBuzz, undated] In Conversation: Bruce K. Redding Jr. | https://biobuzz.io/in-conversation-bruce-k-redding-jr-ceo-of-transdermal-specialties-global/

3. [PRWeb, October 2020] Transdermal Specialties Global (TSG) announces that it has relocated to Frederick MD | https://www.prweb.com/releases/Transdermal_Specialties_Global_TSG_announces_that_it_has_relocated_to_Frederick_MD/prweb17447086.htm

4. [Justia Patents Search, undated] Bruce Redding Inventions, Patents and Patent Applications - Justia Patents Search | https://patents.justia.com/inventor/bruce-redding

5. [PacerMonitor, 2021] Transdermal Specialties Global, Inc. Bankruptcy | https://www.pacermonitor.com/public/case/40302714/Transdermal_Specialties_Global,_Inc

6. [company website, undated] Leadership | https://u-strip.com/leadership/

7. [company website, 2024] New Five-Day Transdermal Insulin Patch | https://u-strip.com/2024/02/28/new-five-day-transdermal-insulin-patch/

8. [Drug Development & Delivery, undated] Transdermal Specialties Announces Success of Insulin Patch Clinical Trial | https://drug-dev.com/transdermal-specialties-announces-success-of-insulin-patch-clinical-trial/

9. [Grand View Research, 2023] Diabetes Care Devices Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/diabetes-care-devices-market

10. [IDF Diabetes Atlas, 2021] IDF Diabetes Atlas 10th edition | https://diabetesatlas.org/atlas/tenth-edition/

11. [Journal of Diabetes Science and Technology, 2018] Needle Phobia and Adherence in Diabetes | https://journals.sagepub.com/doi/10.1177/1932296818755325